Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study

11Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We studied the penetration of etravirine and HIV shedding in the genital tract among 12 HIV-1-infected women receiving an etravirine-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median etravirine concentrations were 663 ng/ml in BP and 857 ng/ml in CVF, with a CVF/BP etravirine ratio of approximately 1.2. This good penetration of etravirine may contribute to the control of viral replication in the female genital tract. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Clavel, C., Peytavin, G., Tubiana, R., Soulié, C., Courbon, E., Crenn-Hebert, C., … Mandelbrot, L. (2012). Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study. Antimicrobial Agents and Chemotherapy, 56(7), 4018–4020. https://doi.org/10.1128/AAC.06474-11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free